+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hyaluronic Acid Market Size, Share & Trends Analysis Report By Application (Dermal Fillers, Osteoarthritis, Ophthalmic, Vesicoureteral Reflux), By Region (North America, APAC, Europe, MEA), And Segment Forecasts, 2019 - 2026

  • ID: 3450702
  • Report
  • Region: Asia Pacific, Europe, North America, United States
  • 100 pages
  • Grand View Research
1 of 3

FEATURED COMPANIES

  • Allergan
  • F. Hoffmann-La Roche AG
  • Fluidigm Corporation
  • Genzyme Corporation
  • LG Life Sciences Ltd
  • Maruha Nichiro, Inc.
  • MORE
The global hyaluronic acid market size is expected to reach USD 15.25 billion by 2026 registering a CAGR of 7.8%, according to this report. Factors, such as increasing concern about toxic chemicals, need for quick and evident results, and shorter recovery time are high impact rendering drivers of this market. The market is witnessing rapid growth due to increasing adoption of aesthetic procedures across the globe.

Wide usage of hyaluronic acid surfaces in cardiovascular implants, such as stents and vascular grafts, for improving the compatibility coupled with growing awareness about anti-aging products is driving the market. In addition, increasing cases of obesity indicate a rising number of people suffering from orthopedic disorders, which do not have any permanent cure and the treatments include pain-killers. However, hyaluronic acid-based viscosupplements are expected to be a possible cure for joint pain. Orthovisc, approved in 2013, and Monovisc, approved in 2016, by Anika Therapeutics, Inc. are among the popular viscosupplements.

Increasing popularity of cosmetic surgeries across the globe is also expected to boost the market growth. In 2013, hyaluronan-based facial fillers received FDA approval, which is used in corrective measures, anti-aging procedure, and filling fine lines. North America led the market in 2018. Presence of key companies, such as Genzyme Corporation and Anika Therapeutics, in this region contributes to market growth. Increasing number of anti-aging procedures performed and resultant demand for dermal fillers are expected to drive the regional market further.

Further key findings from the study suggest:
  • Rising cases of obesity resulting in increased number of cases of osteoarthritis and joint pain has boosted the demand for hyaluronic acid injections as treatment
  • According to the studies, the number of people suffering from osteoarthritis is expected to grow from 53 million in 2012 to 78 million by 2040
  • Asia Pacific is anticipated to emerge as the fastest-growing regional market during the forecast period due to growing geriatric population in China and Japan, which provides a large customer base for anti-aging products and services
  • Some of the key companies in the global hyaluronic acid market are F. Hoffmann-La Roche Ltd., Seikagaku Corp., Galderma S.A., Sanofi (Genzyme), Anika Therapeutics, Inc., Salix Pharmaceuticals, Zimmer Holdings, Inc., Allergan, Inc., Ferring Pharmaceuticals, Inc., and Smith & Nephew Plc

Please note: This product will be delivered within 48 business hours after receipt of order.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Allergan
  • F. Hoffmann-La Roche AG
  • Fluidigm Corporation
  • Genzyme Corporation
  • LG Life Sciences Ltd
  • Maruha Nichiro, Inc.
  • MORE
Chapter 1 Methodology & Scope
1.1 Market Segmentation & Scope
1.1.1 Application
1.1.2 Regional
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.3.5.1 Data for primary interviews in North America
1.3.5.2 Data for primary interviews in Europe
1.3.5.3 Data for primary interviews in Asia Pacific
1.3.5.4 Data for primary interviews in Latin America
1.3.5.5 Data for primary interviews in MEA
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.2 Volume Price Analysis (Model 2)
1.6.2.1 Approach 2: Volume Price Analysis
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2

Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.2.1 Application
2.2.2 Region
2.2.3 Competitive Insights
2.3 Market Outlook

Chapter 3 Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Market segmentation
3.2.1 Market Driver Analysis
3.2.2 Market Restraint Analysis
3.3 Penetration & growth prospect mapping
3.4 Hyaluronic Acid Market Analysis Tools
3.4.1 PEST - SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
3.4.2 Industry Analysis - Porter’s
3.4.3 Major Delas And Strategic Analysis
3.4.3.1 Joint ventures, mergers and acquisition
3.4.3.2 Licensing & partnerships, technology collaborations

Chapter 4 Hyaluronic Acid Market: Application Estimates & Trend Analysis
4.1 Hyaluronic Acid market: Application Movement Analysis
4.2 Dermal Fillers
4.2.1 Dermal Fillers Market, 2015 - 2026 (USD Million)
4.3 Osteoarthritis
4.3.1 Osteoarthritis Market, 2015 - 2026 (USD Million)
4.3.2 Single Injection
4.3.2.1 Single injection market, 2015 - 2026 (USD Million)
4.3.3 Three Injection
4.3.3.1 Three injection market, 2015 - 2026 (USD Million)
4.3.4 Five Injection
4.3.4.1 Five injection market, 2015 - 2026 (USD Million)
4.4 Ophthalmic
4.4.1 Ophthalmic Market, 2015 - 2026 (USD Million)
4.5 Vesicoureteral reflux
4.5.1 Vesicoureteral reflux Market, 2015 - 2026 (USD Million)

Chapter 5 Hyaluronic Acid Market: Regional Estimates & Trend Analysis
5.1 Hyaluronic Acid Market Share, by Region, 2018 & 2026
5.2 North America
5.2.1 North America Hyaluronic Acid Market, 2015 - 2026 (USD Million)
5.2.2 U.S
5.2.2.1 U.S hyaluronic acid market, 2015 - 2026 (USD Million)
5.2.3 Canada
5.2.3.1 Canada hyaluronic acid market, 2015 - 2026 (USD Million)
5.3 Europe
5.3.1 Europe Hyaluronic Acid Market, 2015 - 2026 (USD Million)
5.3.2 U.K.
5.3.2.1 U.K. hyaluronic acid market, 2015 - 2026 (USD Million)
5.3.3 Germany
5.3.3.1 Germany hyaluronic acid market, 2015 - 2026 (USD Million)
5.3.4 France
5.3.4.1 France hyaluronic acid market, 2015 - 2026 (USD Million)
5.3.5 Italy
5.3.5.1 Italy hyaluronic acid market, 2015 - 2026 (USD Million)
5.3.6 Spain
5.3.6.1 Spain hyaluronic acid market, 2015 - 2026 (USD Million)
5.4 Asia Pacific
5.4.1 Asia Pacific Hyaluronic Acid Market, 2015 - 2026 (USD Million)
5.4.2 India
5.4.2.1 India hyaluronic acid market, 2015 - 2026 (USD Million)
5.4.3 China
5.4.3.1 China hyaluronic acid market, 2015 - 2026 (USD Million)
5.4.4 Japan
5.4.4.1 Japan hyaluronic acid market, 2015 - 2026 (USD Million)
5.5 Latin America
5.5.1 Latin America Hyaluronic Acid Market, 2015 - 2026 (USD Million)
5.5.2 Brazil
5.5.2.1 Brazil hyaluronic acid market, 2015 - 2026 (USD Million)
5.5.3 Mexico
5.5.3.1 Mexico hyaluronic acid market, 2015 - 2026 (USD Million)
5.6 MEA
5.5.1 MEA Hyaluronic Acid Market, 2015 - 2026 (USD Million)
5.5.2 South Africa
5.5.2.1 South Africa hyaluronic acid market, 2015 - 2026 (USD Million)

Chapter 6 Reimbursement Scenario
6.1 Reimbursement by Product
6.1.1 Gel-one
6.1.2 EUFLEXXA
6.1.3 Synvisc-One
6.1.4 Supartz
6.1.5 Hyalgan
6.1.6 Monovisc
6.1.7 Orthovisc
6.1.8 Juvéderm, Emervel, Restylane, Macrolane, Belotero, Filorga, Jalupro, Princess, Teosyal, Stylage, Filorga and others
6.2 Reimbursement by Region
6.2.1 U.S.
6.2.2 Canada
6.2.3 China
6.2.4 Japan
6.2.5 India
6.2.6 Brazil
6.2.7 South Africa
6.2.8 Europe

Chapter 7 Competitive Landscape
7.1 Recent Developments & Impact Analysis, by Key Market Participants
7.2 Strategy Framework
7.3 Vendor Landscape
7.3.1 List Of Key Distributors And Channel Partners
7.3.2 Strategy Mapping
7.3.2.1 Partnerships
7.3.2.2 Launch of new product
7.3.2.3 Merger & acquisition
7.3.2.4 Geographical expansion
7.3.2.5 Marketing & promotions
7.4 Company Market Position Analysis (Revenue, Geographic Presence, Product Portfolio, Strategic Initiatives, Employee Strength)
7.5 Company Profiles
7.5.1 Allergan
7.5.1.1 Company overview
7.5.1.2 Financial performance
7.5.1.3 Product benchmarking
7.5.1.4 Strategic initiatives
7.5.1.5 SWOT analysis
7.5.2 Sanofi
7.5.2.1 Company overview
7.5.2.2 Financial performance
7.5.2.3 Product benchmarking
7.5.2.4 Strategic initiatives
7.5.2.5 SWOT analysis
7.5.3 Genzyme Corporation
7.5.3.1 Company overview
7.5.3.2 Financial performance
7.5.3.3 Product benchmarking
7.5.3.4 Strategic initiatives
7.5.3.5 SWOT analysis
7.5.4 Anika Therapeutics, Inc.
7.5.4.1 Company overview
7.5.4.2 Financial performance
7.5.4.3 Product benchmarking
7.5.4.4 Strategic initiatives
7.5.4.5 SWOT analysis
7.5.5 Salix Pharmaceuticals, Inc.
7.5.5.1 Company overview
7.5.5.2 Financial performance
7.5.5.3 Product benchmarking
7.5.5.4 Strategic initiatives
7.5.5.5 SWOT analysis
7.5.6 Seikagaku Corporation
7.5.6.1 Company overview
7.5.6.2 Financial performance
7.5.6.3 Product benchmarking
7.5.6.4 Strategic initiatives
7.5.6.5 SWOT analysis
7.5.7 F. Hoffmann-La Roche AG
7.5.7.1 Company overview
7.5.7.2 Financial performance
7.5.7.3 Product benchmarking
7.5.8 Galderma S.A.
7.5.8.1 Company overview
7.5.8.2 Financial performance
7.5.8.3 Product benchmarking
7.5.8.4 Strategic initiatives
7.5.8.5 SWOT analysis
7.5.9 Zimmer Biomet
7.5.9.1 Company overview
7.5.9.2 Financial performance
7.5.9.3 Product benchmarking
7.5.9.4 Strategic initiatives
7.5.9.5 SWOT analysis
7.5.10 Smith & Nephew Plc
7.5.10.1 Company overview
7.5.10.2 Financial performance
7.5.10.3 Product benchmarking
7.5.10.4 Strategic initiatives
7.5.10.5 SWOT analysis
7.5.11 Ferring B.V.
7.5.11.1 Company overview
7.5.11.2 Product benchmarking
7.5.11.3 Strategic initiatives
7.5.12 Lifecore Biomedical, LLC
7.5.12.1 Company overview
7.5.12.2 Financial performance
7.5.12.3 Product benchmarking
7.5.12.4 Strategic initiatives
7.5.12.5 SWOT analysis
7.5.13 HTL Biotechnology
7.5.13.1 Company overview
7.5.13.2 Product benchmarking
7.5.14 Shiseido
7.5.14.1 Company overview
7.5.14.2 Financial performance
7.5.14.3 Product benchmarking
7.5.14.4 Strategic initiatives
7.5.14.5 SWOT analysis
7.5.15 Bloomage Freda Biopharm Co. Ltd.
7.5.15.1 Company overview
7.5.15.2 Product benchmarking
7.5.15.3 Strategic initiatives
7.5.16 LG Life Sciences Ltd
7.5.16.1 Company overview
7.5.16.2 Product benchmarking
7.5.16.3 Strategic initiatives
7.5.17 Maruha Nichiro, Inc.
7.5.17.1 Company overview
7.5.17.2 Financial performance
7.5.17.3 Product benchmarking
7.5.17.4 Strategic initiatives
7.5.17.5 SWOT analysis
7.5.18 Fluidigm Corporation
7.5.18.1 Company overview
7.5.18.2 Financial performance
7.5.18.3 Product benchmarking
7.5.18.4 Strategic initiatives
7.5.18.5 SWOT analysis

Chapter 8 Recommendations

*Full List of Tables and Figures Available on Enquiry.
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Allergan
  • Sanofi
  • Genzyme Corporation
  • Anika Therapeutics, Inc.
  • Salix Pharmaceuticals, Inc.
  • Seikagaku Corporation
  • F. Hoffmann-La Roche AG
  • Galderma S.A.
  • Zimmer Biomet
  • Smith & Nephew Plc
  • Ferring B.V.
  • Lifecore Biomedical, LLC
  • HTL Biotechnology
  • Shiseido
  • Bloomage Freda Biopharm Co. Ltd.
  • LG Life Sciences Ltd
  • Maruha Nichiro, Inc.
  • Fluidigm Corporation
Note: Product cover images may vary from those shown
Adroll
adroll